Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Complete Purchase of Ventana Today

NEW YORK (GenomeWeb News) – Roche said today that it has completed the tender offer for Ventana’s outstanding shares and that it expects to wrap up the acquisition of the firm later today “without a vote or meeting of Ventana’s shareholders.”
Roche said that its wholly owned subsidiary Rocket Acquisition Corporation has purchased 34,545,323 shares of Ventana common stock, representing approximately 93.7 percent of the company’s outstanding shares. The total value of the purchase is around $3.4 billion.
Following the merger, all Ventana shares not owned by Roche and its subsidiaries will be converted into the right to receive the same cash consideration that was paid in the tender offer.
"Ventana broadens Roche's diagnostic offerings and complements Roche's strong existing position in in vitro diagnostic systems,” said Franz Humer, chairman and CEO of Roche, in a statement. “Incorporating Ventana will enhance our position as the world's leading, personalized healthcare company."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.